Clinical trials: LAM
HIV Infections
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir.
- Trial name
- NCT03016533
- Testing
- Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets
- Where
- 17 sites in United States, Botswana and 5 more
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare
HIV Infection, Metabolic Syndrome
Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience
Background: The primary goal of antiretroviral therapy is to prevent HIV-associated morbidity and mortality. The effectiveness of first-line regimens is supported by a large number of clinical trials; current concerns focus on…
- Conditions
- HIV Infection, Metabolic Syndrome, Antiretroviral Treatment
- Trial name
- TEOTL (NCT07031063)
- Testing
- DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- Where
- Mexico
- Volunteers
- 124 people
- Sponsor
- Instituto Mexicano del Seguro Social
HIV
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection.
- Trial name
- NCT01386970
- Testing
- zidovudine 300mg and lamivudine 150mg as Combivir
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HIV Infections, Hepatitis B
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking…
- Trial name
- NCT00051090
- Testing
- Telbivudine, Lamivudine, Efavirenz
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Cirrhosis
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection.
- Trial name
- NCT00275652
- Testing
- LdT (Telbivudine) and lamivudine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Human Immunodeficiency Virus (HIV)
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439A) 100 mg +…
- Trial name
- DRIVE-AHEAD (NCT02403674)
- Testing
- Doravirine, Tenofovir, Lamivudine, ATRIPLA™
- Volunteers
- 734 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Tuberculosis
Lipoarabinomannan (LAM) Enzyme-Linked Immunosorbent Assay (ELISA) in Diagnostics of Childhood Tuberculosis (TB)
In children, it remains quite difficult even in developed countries, to prove a diagnosis of Tuberculosis (TB). New means for diagnosis of this disease are currently being researched.
- Trial name
- NCT00512330
- Where
- Malawi
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Infection, Human Immunodeficiency Virus, HIV Infections
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (tenofovir…
- Trial name
- NCT02831764
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Where
- 105 sites in United States, Argentina and 16 more
- Volunteers
- 722 people
- Sponsor
- ViiV Healthcare
HIV Infections
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
This study will investigate whether the simplified regimen of a once daily fixed dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate [DF]) will be associated with a reduced rate of adverse events, seen…
- Trial name
- NCT00323544
- Testing
- zidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus I
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
This is a study in healthy adult subjects to evaluate the bioequivalence of a Combined Formulated Tablet compared with maraviroc and Combivir administered concurrently versus maraviroc + Combivir.
- Trial name
- NCT01597648
- Testing
- Maraviroc, Combivir, GSK2838510
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Tuberculosis
Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
Raltegravir is a potent antiretroviral agent that could be used as an alternative to efavirenz in HIV-1 infected patients with tuberculosis.
- Trial name
- NCT00822315
- Testing
- efavirenz, raltegravir
- Where
- 9 sites in Brazil, France
- Volunteers
- 155 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-2 Infection
First-Line Treatment for HIV-2
FIT-2 is a multi-country, phase IIb, randomized, non-comparative study, carried out in West Africa (Côte d'Ivoire, Burkina Faso, Senegal, Togo).
- Trial name
- FIT-2 (NCT02150993)
- Testing
- Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 210 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal
The purpose of this study is to determine the safety and effectiveness of the anti-HIV drugs efavirenz and lamivudine/zidovudine given to treatment-naive HIV-infected people in Dakar, Senegal.
- Trial name
- NCT00100568
- Testing
- Efavirenz, Lamivudine/zidovudine
- Where
- 2 sites in Senegal
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens.
- Trial name
- NCT03682848
- Testing
- DTG + 3TC FDC
- Where
- 8 sites in Kenya, South Africa and 1 more
- Volunteers
- 32 people
- Sponsor
- ViiV Healthcare
HIV Infections
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
This is a 2-part, single-dose, open label, randomized 3-way cross-over study to compare BA of pediatric study drugs TRIUMEQ and (DTG/3TC) in healthy volunteers under fasted conditions. Study will be conducted in 2-parts.
- Trial name
- NCT03441984
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)
The aim of the study is to find short course alternatives to single dose (sd)nevirapine for the prevention of mother-to-child HIV-transmission with the same or better degree of transmission protection than sd nevirapine but with…
- Trial name
- NCT00346567
- Testing
- Zidovudine and Lamivudine (Combivir), Emtricitabine and Tenofovir (Truvada)
- Where
- Tanzania
- Volunteers
- 566 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HIV Infections
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639…
- Trial name
- NCT00002155
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Pharmacokinetic Study Of EPZICOM Tablet
This study was designed to explore the drug levels in the blood in Japanese HIV-infected patients taking EPZICOM tablet at least for 2 weeks prior to administration of the study drug.
- Trial name
- NCT00337922
- Testing
- Lamivudine / Abacavir Sulfate
- Where
- 4 sites in Japan
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Lymphangioleiomyomatosis
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Specific Aim 1: To investigate whether, in Lymphangioleiomyomatosis (LAM) patients, the combination of sirolimus and hydroxychloroquine is safe and well tolerated Specific Aim 2: To investigate whether, in LAM patients, 6 months…
- Trial name
- SAIL (NCT01687179)
- Testing
- "Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital